<DOC>
	<DOCNO>NCT00300027</DOCNO>
	<brief_summary>The purpose study define recommend dose BMS-582664 could safely combine 5-fluorouracil , leucovorin , irinotecan ( FOLFIRI ) 5-fluorouracil , leucovorin , oxaliplatin ( FOLFOX ) chemotherapy regimens patient advance gastrointestinal malignancy evaluate safety profile , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) combination .</brief_summary>
	<brief_title>Study BMS-582664 Combination With Either FOLFIRI FOLFOX Gastrointestinal ( GI ) Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<criteria>Good performance status Advanced colorectal , pancreatic , esophageal gastric cancer Tissue analyse Adequate bone marrow , hepatic , renal function 46 week since prior therapy Adequate protection woman child bear potential ( WOCBP ) Brain metastasis Thromboembolic disease Cardiovascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Advanced Gastrointestinal Malignancies</keyword>
</DOC>